ABSTRACT-To study endothelin receptor subtypes that mediate the smooth muscle contraction of human saphenous vein, effects of some endothelin-receptor agonists and antagonists were examined. Endothelin (ET)-l and sarafotoxin 6b (S6b) elicited potent concentration-dependent contractions with similar pD2 values and similar maximal responses. Selective ETB-receptor agonists, sarafotoxin 6c (S6c) and IRL1620 (Suc-[Glu9, Ala'!'15]-endothelin-1(8-21)), also caused contractions, but their maximal responses were about one third of that of ET-1. ET-3 showed a biphasic concentration-response
peptide, originally isolated from the culture media of porcine aortic endothelial cells (1) . Three endogenous endothelin isopeptides, ET-1, ET-2 and ET-3, and at least two distinct endothelin receptors, ETA and ETB, are currently known (2) . The ETA-receptor has a higher affinity for ET-1 and ET-2 than for ET-3 (3), and the ETB-receptor is non-selective to all three endothelin isopeptides (4). It is well-known that ETA-receptors mediate vascular smooth muscle contractions in many arteries, but considerable evidence is now accumulating that ETB-receptors on vascular smooth muscle are also involved in endothelin-induced vasoconstriction in some blood vessels, especially in veins or some particular vascular beds; e.g., the rabbit saphenous vein (5 -7), the rabbit jugular vein (8) , the rat renal vascular bed (9) and the porcine pulmonary vein (10) .
Recent development of specific endothelin-receptor agonists and antagonists has accelerated more precise pharmacological characterization of the endothelinreceptor subtypes, and this has suggested the heterogeneity of endothelin-receptor subtypes in various tissues (11) . For example, some ET-1-induced responses, in which the agonist selectivity implied the involvement of ETA-receptors, have been shown to be substantially insensitive to ETA-receptor antagonists such as BQ-123 (cyclo(-D-Asp-L-Pro-D-Val-L-Leu-D-Trp-)) and FR139317 ((R)-2-{(S)-2-([ 1-{hexahydro-1H-azepynyl}carbonyl]-amino-methylpentamoyl) } -amino-3-(3 [ 1-methyl-1 H-indolyl] )propionylamino-3-(2-pyridyl)propionic acid). In these cases, some investigators have suggested that two subtypes of ETAreceptors may exist (6, 12) , but others have referred to their observations as "novel", "atypical" or "non-ETA, non-ETB" endothelin receptors (13 -15) . Similarly, heterogeneity of ETB-receptors has been pointed out by the use of some ETA/ETB-receptor antagonists such as PD 142893 (Ac-D-Dip-Leu-Asp-Ile-Ile-Trp) or selective ETB-receptor antagonists such as IRL1038 ([Cys11-Cys15]ET-1(11-21)) or RES-701-1 (cyclic(Glyl-Asp9)(Gly-Asn-Trp-His-GlyThr-Ala-Pro-Asp-Trp-Phe-Asn-Tyr-Tyr-Trp) (6, 7, 10, (16) (17) (18) .
Regarding the endothelin-receptor subtypes of human vascular tissues, some reports have suggested that endothelin-induced contraction is predominantly mediated by ETA-receptors (19, 20) , but ETB-receptors or atypical endothelin receptors as mentioned above may also be involved, at least in part, in human small arteries or veins (11, 12, 21, 22) . Therefore, for further definitive pharmacological characterization of the endothelin-receptor subtypes on the human venous smooth muscle cells, we investigated the effects of BQ-123 and PD142893 on the contractions induced by some endothelin receptor agonists in isolated human saphenous vein.
MATERIALS AND METHODS

Tissue preparation
Sections (1-3 cm) of human saphenous veins were obtained from veins prepared for coronary bypass surgery and used the same day. After careful dissection to remove the connective tissue in a cold modified Krebs-Ringer bicarbonate solution, the veins were cut into rings of 2 mm in length. The vascular endothelium was removed by gentle mechanical rubbing of the internal surface. Each ring preparation was then mounted horizontally between two stainless steel hooks in an organ chamber filled with 5 ml of modified Krebs-Ringer bicarbonate solution. One hook was connected to a micrometer for control of the tissue length, the other to a force transducer (TB-612T; Nihon Kohden, Tokyo) for isometric force recording. The Krebs solution was aerated constantly with a 95% 02 and 5 % CO2 gas mixture and maintained at 37C. Endothelium removal from each ring was verified by the absence of a relaxant response to substance P (0.1 pM) in rings precontracted with phenylephrine (3.0 1M).
Experimental procedures
During an initial equilibration period of 60 min, rings of the saphenous veins were stretched by resting loads of 1.0 g. Then the contractility of each preparation was examined by increasing the KC1 concentration in the bathing medium to 80 mM. Such K+ deporalization was repeated at intervals of 30-40 min until the contractile response attained steady state (usually 3 -4 times). Cumulative concentration-response curves for endothelin or sarafotoxin peptides were then constructed by increasing the concentration in the organ chamber in half-log increments. Contractile responses induced by these agonists were expressed in terms of percent of the above-mentioned maximal response to KC1. When the effects of BQ-123 and PD142893 were to be examined, each compound was added to the organ chamber 15 -20 min before addition of the first dose of the agonists. When ethanol or methanol was used as a solvent, the final concentration of the vehicle did not exceed 0.3010 or 1.0010, respectively, and they showed no significant influence on the contractile responses in the present experiments.
Drugs and solutions
The composition of modified Krebs-Ringer bicarbonate solution used in the present study was as follows: 118. 4 The data were evaluated statistically by Student's t-test. Values were considered to differ significantly when the probability values were less than 0.05. In experiments with BQ-123, Schild plots were constructed. The dose ratios of concentrations of ET-1 or S6b eliciting 50% of the maximal contraction to each agonist in the presence and absence of BQ-123 were used. The pA2 values were calculated by linear regression analysis, if the slope of the plot did not differ significantly from unity.
RESULTS
Effects of ET-1 and related peptides on the human saphenous vein Figure 1 shows contractile effects of 0.1 nM -1.0 pM ET-1 and related peptides on the human saphenous vein. ET-1 and S6b elicited concentration-dependent contractions with similar pD2 values (8.21±0.10 for ET-1, n=9 and 8.11-L0.07 for S6b, n=7) and similar maximal responses (124.2±4.1010 for ET-1, n=9 and 127.7±5.3% for S6b, n=7). Selective ETB-receptor agonists, S6c and IRL1620, also caused contractions, but their maximal responses were about one third of that of ET-1 (40.3±4.7% for S6c, n=7 and 40.6±4.4% for IRL1620, n = 7).
When ET-3 was applied cumulatively to the human saphenous vein, 0.1-10 nM ET-3 caused concentration- Contractions induced by 0.1-100 nM ET-3 were not inhibited at all by 3 pM BQ-123, while those induced by concentrations higher than 300 nM were markedly suppressed (Fig. 3A) . Consequently, the concentrationresponse curve for ET-3 in the presence of BQ-123 was monophasic, in contrast to the biphasic curve observed in the absence of this antagonist, as described above. The concentration-response curves for S6c and IRL1620 were not affected significantly by 3 pM BQ-123 in the entire concentration range tested (Fig. 3 : B and C). However, PD142893 (10 pM) markedly inhibited S6b-induced contractions, when concentrations of S6b were higher than 10 nM (Fig. 4B) . Similarly, contractions induced by ET-3 in concentrations higher than 100 nM were inhibited by PD142893 (10 pM), although contractions induced by low concentrations of S6b and ET-3 were resistant to PD142893 (Fig. 4: B and C) .
Contractions induced by 1.0-10 nM S6c were suppressed by 10 pM PD142893, but the maximal responses were unaffected (Fig. 5A) . The pD2 values for S6c in the absence and presence of this antagonist were 9.02±0.05
(n = 7) and 8.03 ± 0.15 (n = 6), respectively, indicating a tenfold rightward shift. In contrast, IRL1620-induced responses were almost completely abolished by the same concentration of PD142893 (Fig. 5B) . tor is known to recognize ET-1, S6b and high concentrations of ET-3 as agonists, but not IRL1620 and S6c. Therefore, the data obtained in this study indicate that the human saphenous vein contains both ETA-and ETBreceptors, although ETB-receptor-mediated responses were much smaller than those mediated by ETA-receptors in this vein. Since ET-3 is known to act as an ETB-receptor agonist at low concentrations, the contractions induced by low concentrations of ET-3 in the human saphenous vein are considered to be ETB-receptormediated responses. On the other hand, at concentrations higher than 100 nM, ET-3 is approximately 100-fold less potent than ET-1. Therefore, the contractions induced by high concentrations of ET-3 are considered to be mediated by ETA-receptors, because ET-3 is known to be less potent as an ETA-receptor agonist than ET-1.
The concentration-response curves for S6c and IRL1620 were not affected by the ETA-receptor antagonist BQ-123. These results are consistent with the interpretation that these responses are mediated by ETBreceptors. Contractions induced by low concentrations of ET-3 and S6b were resistant to BQ-123, whereas contractions induced by high concentrations of these agonists were very sensitive to BQ-123 (Figs. 3A and 2B ). These observations imply the involvement of ETA-receptors in the BQ-123-sensitive components of these contractions and the involvement of ETB-receptors in the BQ-123-resistant components.
However, ET-1 was much more resistant to BQ-123 than S6b in the entire concentration range tested in this study (Fig. 2) . The pA2 values against ET-1 and S6b indicate an approximately 20-fold difference in the antagonistic potency and may imply the heterogeneity of endothelin receptors. Similarly, the ETA/ETB-receptor antagonist PD142893 hardly affected the contractile effect of ET-1, while it markedly antagonized the contractile effects of high concentrations of ET-3 and S6b in the present experiments.
Probably, the ET-1-and S6b-mediated responses were mediated by ETA-receptor subtypes, because S6c-and IRL1620-induced contractions were much weaker than ET-1-and S6b-induced contractions. In support of this view, similar potent contractile responses to ET-1 and S6b with different sensitivity to BQ-123 were observed after desensitization of ETB-receptors by pretreatment with S6c in the human saphenous vein (M. Nishiyama et al., unpublished data). The simplest explanation for these results may be to assume that ET-1 and S6b exert their effects through two different ETA-receptor subtypes, one subtype that is highly sensitive to BQ-123 and PD142893 and the other, much less sensitive to these antagonists. S6b and high concentrations of ET-3 may be recognized by the former subtype, whereas the ET-1-induced response may be mediated by the latter subtype. Endothelin receptors are currently classified primarily according to the rank order of binding affinities or pharmacological potencies of endothelin isopeptides, but also according to those of some antagonists. Pharmacologically, in typical ETA-receptor-mediated responses, it is expected that ET-1 is more potent than ET-3, that BQ-123 or FR139317 is effective as an antagonist, and that ETB-receptor-selective compounds (for example, S6c, IRL1620 or [Ala' '3,11,15] ET-1) have no effect. Similarly, in typical ETB-receptor-mediated responses, it is expected that ET-3 is as potent as ET-1, that BQ-123 or FR139317 is ineffective as an antagonist, and that ETBreceptor agonists are fully active. At present, however, there is a considerable number of reports indicating that ET-1-induced responses in some cases are curiously much more resistant to BQ-123 than ET-3-or S6b-induced responses. The responsible receptors are sometimes called "atypical" , but possibly, they belong to the ETA-receptors, since ETA-receptor antagonists are moderately or highly potent and selective ETB-receptor agonists are usually inactive (11) . In such cases, it is conceivable that ET-1 and S6b (or ET-3) may exert their actions through two different types of ETA-receptors. Sudjarwo et al. have proposed the classification of the ETA-receptors into a BQ-123-sensitive (tentatively termed ETA1) subtype and a BQ-123-insensitive (tentatively termed ETA2) subtype (6) . The present results suggested that both subtypes are located in the human saphenous vein, and indicated that the BQ-123-sensitive response is also sensitive to PD142893, and that the BQ-123-insensitive response is insensitive to PD 142893.
On the other hand, IRL 1620-induced contractions of the human saphenous vein were resistant to BQ-123, but markedly inhibited by PD142893, indicating involvement of ETB receptors. Contractions induced by S6c were also insensitive to BQ-123, but in contrast to IRL1620, they were relatively insensitive to PD142893 (Fig. 5) . Contractions induced by low concentrations of ET-3 and S6b were also resistant to PD142893 (Fig. 4) . Although both IRL 1620 and S6c are known selective ETB-receptor agonists, their sensitivities to PD142893 were markedly different. It suggests again the involvement of the heterogeneous subtypes of ETB-receptors in the endothelininduced contraction of human saphenous vein. Recent studies have demonstrated that some ETB-receptor antagonists such as IRL1038 or RES-701-1, as well as the ETA/ETB antagonist PD142893, are quite ineffective in antagonizing ETB-receptor-mediated contractile responses of some vascular smooth muscles, in spite of their potent antagonistic effects on the vasodilation mediated by ETB-receptors on endothelial cells (6, 7, 10, 11, 16 -18) . One possible way to explain these findings is to assume the existence of two ETB-receptor subtypes, and it has been proposed that the ETB-receptor subtype sensitive to these antagonists should be termed ETB1 and the other insensitive subtype, ETB2 (17, 18) . Although the ETB-receptor subtypes mediating vasorelaxation and vasoconstriction are sometimes designated as ETB1 and ETB2, respectively (23), the antagonistic potency may be more adequate as a criterion for pharmacological classification of ETB-receptors than the types of responses, as it is possible that both subtypes are located on the smooth muscle and mediate vasoconstriction (7) . From a binding study, it has been reported that ETB-receptors in the rabbit saphenous vein is made up of two components with different affinities for ET-3 and S6c (24) . This finding seems to support the idea of two different ETB-receptor subtypes, although it is not known how the two binding components correspond to the two ETB-receptor subtypes discussed above. Present pharmacological results suggest that the human saphenous vein contains both ETB1 (sensitive to PD142893)-and ETB2 (resistant to PD142893)-receptors, in addition to the ETA-subtypes mentioned above.
In addition to ETA-and ETB-receptors, a possibility of a third endothelin receptor cannot be denied. The identification of a cDNA encoding a novel ETA-receptor with relatively high affinity for ET-3 has been reported in Xenopus dermal melanophores (25) . However, it is not yet clear whether it actually represents a species variant of ETA-or ETB-receptors, or whether it is a distinct subtype, ETA, that is highly selective to ET-3 and has a distinct mammalian homologue. Recently, Douglas et al. have reported that the low affinity site in the rabbit lateral saphenous vein has the characteristics of an ETA-receptor, since ET-3 and S6c were significantly more potent than ET-1 (26) . Because of the scarcity of evidence for the presence of an ETA-receptor molecule mediating the ETctype responses and the lack of selective ETA-receptor ligands other than ET-3, it appears too premature to discuss whether the above mentioned BQ-123-sensitive response to ET-3 or S6b are related to the ETA-receptor.
In spite of the accumulation of pharmacological evidence for the existence of additional endothelin receptor subtypes, its possibility is still controversial. At present, only two endothelin receptors, ETA and ETB, have so far been cloned (2) . In the rabbit saphenous vein, low stringency Northern analysis with ETA-and ETB-receptor cDNA probes failed to detect additional RNA species other than those of the known ETA-and ETB-receptors (26) . If there is no other endothelin receptor subtype, an alternative explanation is necessary to account for the apparent heterogeneous responses to endothelins, although we cannot rule out the possibility that different post-translational modification results in the receptor heterogeneity. Since pharmacological responses can be influenced by many factors, the observed atypical responses may be mediated by the known ETA-and ETBreceptors. For example, it is possible that different association/dissociation rates for receptor-ligand complexes or a difference in their internalization might affect functional observations. Another possibility is that differences in antagonistic potency might reflect differential binding characteristics of agonists and antagonists to distinct subdomains of a single type of receptor. Alternatively, if ETA-and ETB-receptors coexist in different ratios in various tissues, their total responses to endothelins might give the impression of different receptor subtypes. In this situation, involvement of multiple intracellular signal transduction systems with the selective trafficking of receptors to different G proteins and/or their possible unknown interactions may be important points for consideration (27) . Biochemical analyses and molecular expression studies using a wide spectrum of both agonists and antagonists seem essential to clarify the pharmacological heterogeneity of the responses to endothelins.
Our present results indicated pharmacological heterogeneity of both ETA-and ETB-receptor-mediated contractions in human saphenous vein, although the maximal responses mediated by ETB-receptors were much smaller than those mediated by ETA-receptors. The currently available data, as well as those obtained in the present study, clearly indicate the pharmacological heterogeneity of responses to endothelins, but they are not yet sufficient to provide conclusive evidence for endothelin receptor nomenclature. Therefore, additional data on the binding characteristics, on the second messenger production and on the DNA nucleotide sequences of the possible novel subtypes are eagerly awaited. 
